Zoetis Inc
NYSE:ZTS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
145.54
200.09
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ZTS stock under the Base Case scenario is 122.82 USD. Compared to the current market price of 173.96 USD, Zoetis Inc is Overvalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zoetis Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ZTS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Zoetis Inc. is a leading global animal health company dedicated to advancing animal care through innovative solutions that enhance the well-being and productivity of livestock and companion animals. Established in 1952 as a former division of the pharmaceutical giant Pfizer, Zoetis transitioned into its standalone identity in 2013 and has since carved out a significant niche in the growing market for animal health products. With a diverse portfolio that includes vaccines, parasiticides, and diagnostic tools, the company serves farmers, veterinarians, and pet owners, contributing to the health of food-producing animals and pets alike. The robust demand for high-quality animal health products—...
Zoetis Inc. is a leading global animal health company dedicated to advancing animal care through innovative solutions that enhance the well-being and productivity of livestock and companion animals. Established in 1952 as a former division of the pharmaceutical giant Pfizer, Zoetis transitioned into its standalone identity in 2013 and has since carved out a significant niche in the growing market for animal health products. With a diverse portfolio that includes vaccines, parasiticides, and diagnostic tools, the company serves farmers, veterinarians, and pet owners, contributing to the health of food-producing animals and pets alike. The robust demand for high-quality animal health products—driven by increasing global food consumption and a growing pet population—positions Zoetis for sustainable growth and offers investors a compelling opportunity.
Financially, Zoetis has demonstrated consistent revenue growth, leveraging its strong market presence and commitment to research and development. The company's strategic investments in new technologies and targeted acquisitions have strengthened its position in key market segments. With a focus on driving innovation and addressing changing consumer needs, Zoetis is poised to benefit from emerging trends such as increased attention to food safety and animal welfare. For investors, this translates to a resilient business model with solid long-term prospects, backed by a proven leadership team and a commitment to maintaining a competitive edge through continuous advancement in animal health solutions.
Zoetis Inc., a global leader in animal health, focuses on the discovery, development, manufacturing, and commercialization of veterinary medicines and vaccines. The company operates primarily through two core business segments:
-
Livestock:
- This segment serves various species including cattle, swine, poultry, sheep, and aquaculture.
- Zoetis provides a comprehensive range of products including anti-infectives, vaccines, and parasiticides that help manage and prevent diseases in livestock.
- The focus is on improving livestock health, productivity, and overall welfare, which is crucial for food safety and supply.
-
companion Animals:
- This segment targets pets such as dogs and cats, offering a diverse portfolio of vaccines, anti-infectives, dermatology products, and other health solutions.
- Growth in this segment is driven by increasing pet ownership and a focus on preventive care, nutrition, and wellness.
- Zoetis also invests in technologies and services that enhance the veterinary clinic experience, including diagnostics and software.
In addition to these core segments, Zoetis continually explores innovation through research and development, aiming to address unmet needs in animal health while adhering to sustainability and welfare standards. The company’s strategy emphasizes growth through new product introductions, expanding into emerging markets, and leveraging partnerships with veterinarians and animal producers.
Zoetis Inc. is a leading global animal health company and has developed several unique competitive advantages that distinguish it from its rivals in the industry. Here are some key advantages:
-
Strong Brand Recognition: Zoetis has established a strong brand reputation in the animal health sector, which is associated with quality and reliability. This brand equity helps attract and retain customers.
-
Diverse Product Portfolio: The company offers a wide range of products, including vaccines, therapeutics, and diagnostics for both livestock and pets. This diversification allows Zoetis to mitigate risks associated with market fluctuations in a specific segment.
-
Robust Research and Development (R&D): Zoetis invests significantly in R&D to innovate and develop new products. This focus on science and technology enables the company to stay ahead of trends and develop proprietary products that can command higher prices.
-
Global Presence: Zoetis operates in over 100 countries, providing access to numerous markets and customer segments. This global footprint allows for economies of scale and the ability to adapt to local market needs.
-
Strong Relationships with Veterinarians and Farmers: Zoetis has built strong partnerships with veterinarians, farmers, and distributors, which enhances customer loyalty and helps ensure the adoption of its products.
-
Focus on Specialty Products: The company has a strong emphasis on specialty products, such as biologics and anti-infectives, which are often required for specific health issues in animals. This focus can lead to higher margins and less competition.
-
Regulatory Expertise: Navigating the complex regulatory environment surrounding animal health products requires specific expertise. Zoetis has a proven track record in achieving necessary approvals and compliance, providing an edge over competitors.
-
Sustainability Initiatives: Zoetis is proactive in addressing sustainability challenges in agriculture and animal health. Initiatives aimed at improving animal welfare and reducing environmental impact resonate with consumers and can create a competitive differentiator.
-
Data and Analytics Capabilities: Leveraging data analytics and digital tools to provide insights to customers enhances product offerings and service support. This capability allows Zoetis to tailor solutions to specific customer needs, improving service delivery.
-
Financial Strength and Stability: With a strong balance sheet and consistent revenue growth, Zoetis has the financial resources to invest in acquisitions, expand R&D, and withstand market downturns, providing a strategic advantage over less financially secure competitors.
These competitive advantages allow Zoetis to maintain a leadership position in the animal health industry, fostering long-term growth and resilience against competitive pressures.
Zoetis Inc., as a leader in the animal health industry, faces several risks and challenges in the near future:
-
Regulatory Environment: The veterinary pharmaceutical industry is highly regulated. Changes in regulations or government policies can impact product approvals, labeling, and marketing practices.
-
Competition: The animal health market is competitive, with numerous players. Emerging biopharmaceutical companies and generic drug manufacturers can put pressure on pricing and market share.
-
R&D and Innovation: Sustaining a robust pipeline of new products is crucial. Delays in research and development, high costs, or failures in clinical trials can hinder growth.
-
Market Demand Fluctuations: Changes in consumer behavior, economic conditions, or livestock prices can affect the demand for animal health products. Economic downturns can lead to reduced spending on veterinary care.
-
Global Supply Chain Disruptions: Natural disasters, geopolitical tensions, or pandemics (like COVID-19) can disrupt raw material supply chains, affecting production capacity and costs.
-
Technological Advancements: Rapid advancements in technology require companies to continuously innovate. Failure to adapt to new technologies, such as digital health solutions or novel delivery systems, could render Zoetis less competitive.
-
Pricing Pressure: Increased cost-consciousness among veterinarians and pet owners can lead to pricing pressure. Additionally, there is growing scrutiny regarding the prices of veterinary products, which may impact margins.
-
Epidemics and Disease Outbreaks: Outbreaks of animal diseases (e.g., avian influenza, foot-and-mouth disease) can impact the livestock market and, consequently, the demand for certain products.
-
Sustainability Challenges: As society becomes increasingly focused on sustainability, Zoetis may face pressure to ensure its products and practices align with environmental and ethical standards.
-
Integration and Mergers: If Zoetis pursues acquisitions or merges with other entities, integration challenges and the realization of expected synergies can pose risks.
Understanding these risks will be crucial for Zoetis as it navigates the competitive and dynamic landscape of the animal health market.
Revenue & Expenses Breakdown
Zoetis Inc
Balance Sheet Decomposition
Zoetis Inc
Current Assets | 6.3B |
Cash & Short-Term Investments | 1.7B |
Receivables | 1.4B |
Other Current Assets | 3.2B |
Non-Current Assets | 8.1B |
PP&E | 3.5B |
Intangibles | 3.9B |
Other Non-Current Assets | 624m |
Current Liabilities | 1.7B |
Accounts Payable | 404m |
Accrued Liabilities | 1.1B |
Other Current Liabilities | 238m |
Non-Current Liabilities | 7.4B |
Long-Term Debt | 6.6B |
Other Non-Current Liabilities | 847m |
Earnings Waterfall
Zoetis Inc
Revenue
|
9.2B
USD
|
Cost of Revenue
|
-2.7B
USD
|
Gross Profit
|
6.4B
USD
|
Operating Expenses
|
-3.1B
USD
|
Operating Income
|
3.3B
USD
|
Other Expenses
|
-907m
USD
|
Net Income
|
2.4B
USD
|
Free Cash Flow Analysis
Zoetis Inc
USD | |
Free Cash Flow | USD |
Zoetis achieved a robust 14% operational revenue growth in Q3 2024, driven by a 15% increase in U.S. sales and a 13% rise internationally. Key products like Librela generated impressive sales, growing 97% year-over-year. The company raised its full-year revenue guidance to between $9.2 billion and $9.3 billion, reflecting a 10% to 11% operational growth. Adjusted net income is expected between $2.67 billion and $2.695 billion, with a projected 13.5% to 14.5% operational growth. Looking ahead, while Q4 may see a slowdown due to recent divestitures, long-term growth remains strong with expanding markets in osteoarthritis treatments and continued innovation.
What is Earnings Call?
ZTS Profitability Score
Profitability Due Diligence
Zoetis Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.
Score
Zoetis Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.
ZTS Solvency Score
Solvency Due Diligence
Zoetis Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Zoetis Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZTS Price Targets Summary
Zoetis Inc
According to Wall Street analysts, the average 1-year price target for ZTS is 222.96 USD with a low forecast of 173.84 USD and a high forecast of 260.4 USD.
Dividends
Current shareholder yield for ZTS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ZTS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The company is headquartered in Parsippany, New Jersey and currently employs 12,100 full-time employees. The company went IPO on 2013-02-01. The firm has a business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within product categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The firm operate its business through two segments: the United States and International. Within each of these operating segments, it offers a product portfolio for both companion animal and livestock customers. The firm market its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and its products are sold in more than 100 countries.
Contact
IPO
Employees
Officers
The intrinsic value of one ZTS stock under the Base Case scenario is 122.82 USD.
Compared to the current market price of 173.96 USD, Zoetis Inc is Overvalued by 29%.